cyrilzakka/clinical-trials huggingface dataset:
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.

PRIMARY OBJECTIVE:

I. To characterize radiation-related functional imaging changes in the heart using sarcoidosis fludeoxyglucose F-18 (FDG) PET-CT imaging.

SECONDARY OBJECTIVES:

I. 1. To evaluate the ability of imaging changes in the heart to predict for overall survival (OS).

II. To evaluate the ability of imaging changes in the heart to predict for cardiac toxicity.

III. To evaluate the ability of imaging changes in the heart to predict for cardiac related death.

EXPLORATORY OBJECTIVES:

I. To evaluate radiation treatment planning strategies to reduce risk of cardiotoxicity.

II. To determine the correlation between sarcoidosis FDG PET-CT scans and oncologic FDG PET-CT scans.

OUTLINE:

Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.

After completion of study treatment, patients are followed up at 12 and 24 months.

Eligibility Criteria:
Inclusion Criteria:

* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for the duration of the study
* Male or female, aged \>= 18
* Life expectancy \>= 3 months as assessed by Radiation Oncologist
* Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose)
* Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer
* Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted

Exclusion Criteria:

* Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
* Palliative radiation doses defined as 20 Gy in 5 fractions
Polish Validation 4AT Tool

Delirium is a phenomenon which affects patients with various disorders and representing various age groups. Screening instruments make it possible to diagnose the condition at an early stage and to prevent its development. The aim of the study is to examine the reliability and validity of the Polish version of the 4AT (Pol4-AT) in patients after cardiac surgery.

Procedure of validation:

After obtaining the author's consent, the original English version of the 4AT was separately translated by 3 centres working on the validation of the Pol4-AT (University of Rzeszów, Poland; University Hospital in England; Karolinska University, Sweden). Then, three translations were compared, to be approved by the project supervisor (Karolinska University). Any doubts arising during the comparison were consulted with the English translator. As a result, one coherent version was accepted and translated back into English. The questionnaire was distributed in a convenient sample of 20 patients to examine the validity of the face. Vague words and statements were changed, and the final version translated into Polish was created. The Pol4-AT was tested for internal consistency and reliability.

Delirium, which generally is triggered by underlying medical conditions, is an acute and fluctuating disorder associated with attention and cognitive defects, and frequently accompanied by excessive arousal and perception-related problems. Delirium may lead to a variety of complications, e.g. cognitive impairments. Development of delirium is promoted by both anaesthesia and pain. Patients subjected to cardiac surgeries are at risk of delirium due to such factors as extracorporeal circulation applied during the intervention and various cardiovascular complications. Rapid identification of the problem may help eliminate avoidable complications which can be prevented at an early stage.

Eligibility Criteria:
Inclusion Criteria:

* adults
* able to sign the consent form
* elective cardiac surgery
* extracorporeal circulation

Exclusion Criteria:

* unconscious patients
* diagnosed mental illness
* patient's lack of consent to participate in the study
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer

RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer.

PURPOSE: This clinical trial is studying how well polyvinylpyrrolidone-sodium hyaluronate gel works in reducing pain from oral mucositis in young patients with cancer.

OBJECTIVES:

* Examine the feasibility and acceptability of polyvinylpyrrolidone-sodium hyaluronate gel in pediatric patients experiencing oral pain from mucositis after cancer therapy.

OUTLINE: This is a prospective, uncontrolled, open-label, pilot, multicenter study.

Beginning before hospital discharge or day 3 after chemotherapy, patients use oral polyvinylpyrrolidone-sodium hyaluronate gel mouth rinse for at least 1 minute, 3 times per day or as needed. Treatment continues for 48 hours. Patients with persistent oral pain may continue treatment with polyvinylpyrrolidone-sodium hyaluronate gel beyond 48 hours.

Oral pain and acceptability (i.e., taste) of polyvinylpyrrolidone-sodium hyaluronate gel are assessed periodically using self-reported rating scales.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of cancer, including, but not limited to, the following:

  * Acute lymphoblastic leukemia
  * Acute myeloid leukemia
  * Brain tumor
  * Hodgkin's lymphoma
  * Non-Hodgkin's lymphoma
  * Sarcoma
  * Wilms' tumor
  * Neuroblastoma
* Meets 1 of the following criteria:

  * Admitted to an in-patient unit after undergoing chemotherapy that is anticipated to cause oral mucositis
  * Admitted to an in-patient unit after undergoing myeloablative therapy followed by peripheral blood stem cell or bone marrow transplantation
* Is experiencing oral pain due to mucositis

PATIENT CHARACTERISTICS:

* No known hypersensitivity to polyvinylpyrrolidone-sodium hyaluronate gel

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Concurrent analgesics allowed
The Effects of Buprenorphine on Responses to Verbal Tasks

In this study, the investigators will examine the effects of buprenorphine, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. Recently it has been shown that buprenorphine, a partial mu-opioid agonist, reduces sensitivity to recognition of fearful facial expressions in humans. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of buprenorphine. The investigators hypothesize that buprenorphine with reduce both physiological and subjective measures of stress.


Eligibility Criteria:
Inclusion Criteria:

* Healthy men and women
* ages 18-40 years
* high school education
* fluent in English

Exclusion Criteria:

* history of adverse drug reactions
* taking oral contraceptives or planning to become pregnant
* taking any medications
* smokers
* night shift workers
* drink more than 4 alcoholic or caffeinated drinks per day
LevetIracetam in Patients Being Treated for Epilepsy

Epilepsy is one of the most common neurological diseases.Approximately 53 million people suffering from chronic recurrent epilepsy in 1990 and that number increased about 58 million in 2005.

The annual incidence of epilepsy varies considerably in different epidemiological studies, ranging from 11 cases per 100,000 general population to 230 cases per 100,000 people.

To date there has been discovered the ideal Antiepileptic Drugs. The drug, ie, that are safe and effective, it has good daily administration frequency, easily administered from all roads, which has high bioavailability, which is not highly bound to proteins, and not holding inductive or inhibitory effect.

There are broad-spectrum anticonvulsant, which means that a drug can be very effective for a patient, but may or may not regulate and increase the frequency of another crisis. Thus there remains now only to choose one among a number of drugs, the most appropriate.This study intends to register within 12 months clinical practice in Greek reality as regards the elements of diagnosis and management of patients with epilepsy and those who already are, or are part of treatment with levetiracetam.

The aims of this clinical study is to record data on

* the diagnosis
* The management of epilepsy in daily clinical practice in a sample of Greek population
* The monitoring of patients entering or already undergoing treatment with levetiracetam.
* The assessment of quality of life between visits of the study by using quality of life QOLIE-31 questionnaire
* The economic evaluation of the change in treatment from original to generic levetiracetam This is a data recording study and evaluation of treatment with levetiracetam. The study will take place in 15 antiepileptic centers throughout Greece. Researchers will have to successively record all incidents of patients (30 per center) with epilepsy, which are new diagnoses or already diagnosed and are treated with levetiracetam.

Eligibility Criteria:
Inclusion Criteria:

* Outpatients
* Males and Females
* Age\> 6 years
* Patients diagnosed with epilepsy or
* Patients who are diagnosed and treated with antiepileptic treatment levetiracetam
* Patients who consent to their participation in the study
* Patients will comply with the requirements and procedures of the study

Exclusion Criteria:

* Patients who did not consent to their participation in the study
* Patients who will not comply to the needs and the design process
Clinical Course Of Disease In Participants With FA-CM

Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)

Study LX2006-02 is a prospective, longitudinal, low-intervention, multicenter, global study aimed at characterizing the nature and rate of cardiac disease progression in participants with genetically confirmed FA-CM.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, ages ≥6 years at the time of signing the informed consent (and assent, if applicable).
* Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles), with onset of FA occurring at ≤25 years of age
* Confirmed left ventricular hypertrophy (LVH)
* Left ventricular ejection fraction ≥40%

Exclusion Criteria:

* Presence of other form(s) of CM contributing to heart failure (HF), clinically significant cardiac anatomic abnormality or congenital cardiac malformation, clinically significant coronary artery, uncorrected, hemodynamically significant primary structural valvular disease not due to CM
* Currently receiving intermittent or continuous intravenous (IV) inotrope infusion, presence of a ventricular assist device, or history of prior heart transplantation
* Contraindication to cMRI
* Prior organ transplantation
* Initiation of cardiac resynchronization therapy (CRT) within 6 months prior to screening.
* History of prior gene transfer or cell therapy.
* Poorly controlled diabetes (hemoglobin A1c ≥8%)
* Active hematologic or solid organ malignancy
Effect of Enhanced External Counterpulsation

This study evaluated the efficacy and safety of enhanced extracorporeal counterpulsation for cardiac rehabilitation in patients after DCB for acute myocardial infarction.


Eligibility Criteria:
Inclusion Criteria:

* patients with AMI diagnosed based on the universal definition of myocardial infarction criteria
* a single vessel infarcted, and Syntax score ≤22
* patients treated using DCB
* patients without EECP contraindications
* patients aged 18-75 years
* patients who had signed informed consent and were able to cooperate in completing the study

Exclusion Criteria:

* patients with lower limb deep venous thrombosis and active thrombophlebitis
* patients with moderate to severe valvular heart disease, especially those with aortic insufficiency and/or stenosis
* patients with moderate to severe pulmonary arterial hypertension (mean pulmonary arterial pressure \>50 mmHg)
* patients with aortic, cerebral or dissecting aneurysms
* patients with uncontrolled hypertension (\>180/110 mmHg)
* patients with decompensated heart failure (cardiac function of grade IV)
* patients with arrhythmia that might interfere with the electrocardiographic gating function of the EECP device
* patients with haemorrhagic diseases or obvious bleeding tendencies
* patients with infected lesions in their limbs that may affect EECP
* pregnant women
* patients with ventricular aneurysm and mural thrombus detected through echocardiography
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.


Eligibility Criteria:
Inclusion Criteria:

* Adult Thai male or female patients aged greater than or equal to (≥) 18 years.
* Diagnosed with T2D either through International Classification of Diseases (ICD) code or by physician's description such as documentation in the medical record, and who have not previously been treated with injectable glucose-lowering medication.
* At least one recent or closest Glycated Haemoglobin (HbA1c) test value available and documented less than or equal to 12 weeks prior to the initiation of oral semaglutide.
* Had initiated oral semaglutide for diabetes during the target selection period of April 2022 to December 2023. All required data for collection should already be accessible prior to the initiation of data collection.
* Treated with oral semaglutide for at least 6 months without interruption or discontinuation.

Exclusion Criteria:

* Previous participation in this study. Participation is defined as having given informed consent in this study (if applicable).
* Participants with any diagnosis of type 1 diabetes (T1D).
* Medical records documenting prior or ongoing treatment with injectable glucose-lowering treatment.
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.

continuous patients with target disorders in collaborating institutions

Eligibility Criteria:
Inclusion Criteria:

* Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion Criteria:

* Non-consenting
* Hypersensitivity to the active substance or to any of the excipients
* galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Remote Ischemic Conditioning in Oncology

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic conditioning (RIC) is feasible in children and young adults receiving anthracycline chemotherapy. The secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive RIC prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

1. Pediatric, adolescent, or young adult patients, 11 years of age or above.
2. Able to tolerate upper arm blood pressure inflation.

Exclusion Criteria:

1. Previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis) or congenital heart disease other than bicuspid aortic valve.
2. Chronic kidney disease as defined as a pre-transplant GFR \<80
3. Central line in both upper extremities.
4. Known peripheral vascular disease or vasculitis.
5. Platelet count less than 30,000.
6. Known clotting disorder or hypercoagulability
7. Non-English-speaking patients.
Effects of Pilates Exercises in Squash Players

To determine the effectiveness of Pilates Exercises on service speed and agility in Squash Players

Squash was originated in England in the early 19th, when a group of schoolchildren noticed that punctured balls could be "squashed" against walls in a wider range of shots and it requires more effort from the player. This variation gained popularity, and the first squash courts were made in 1864; and the sport of squash was formally formed. Squash is a racquet sport in which two players compete with a hollow rubber ball on a court surrounded on four sides by walls. The players alternate hitting the ball using racquets. The ball can bounce once on the ground and as many times as the court walls allow. Squash players' main approach is to compel their opponents to go around the entire playing field. If this tactics is successful, the challenger travels a greater distance and puts a higher load on the body.

The purpose of this study is to determine the effectiveness of pilates exercises on service speed and agility in squash players.

Eligibility Criteria:
Inclusion Criteria:

* Active squash player
* Players playing squash for \> 1 year
* Players engaging in squash ≥ 3 days in a week

Exclusion Criteria:

* History of any injury in past 6 months
* Those players having musculoskeletal, neurological and cardiovascular problems
* Those players who have any medical conditions
Effects of General Anesthesia on Quality of Recovery After Transaxillary Endoscopic Breast Augmentation

Among aesthetic or cosmetic surgeries, breast augmentation was the most frequently performed and the endoscopic transaxillary approach has become the preferred incision for Asian women. As breast augmentation must be performed under general anesthesia accompanied by its effects and potential complications, types of general anesthesia may affect the quality of recovery. Currently, the two most common techniques of general anesthesia are inhalation anesthesia (IH) and total intravenous anesthesia (TIVA). The effects of these types of general anesthesia on the quality of recovery have been investigated for numerous surgical procedures. However, no prior studies have analyzed different types of anesthesia used for performing transaxillary endoscopic breast augmentation. This prospective, parallel, randomized controlled study will evaluate the effects of inhalation anesthesia vs. total intravenous anesthesia on the quality of recovery in patients undergoing transaxillary endoscopic breast augmentation.


Eligibility Criteria:
Inclusion Criteria:

* Patients are appropriate for undergoing transaxillary endoscopic breast augmentation
* Age between 20-65 years
* Physical Status I or II as defined by the American Society of Anesthesiologists (ASA) Physical Status Classification System

Exclusion Criteria:

* Having difficulty reading or hearing
* Diagnosed with addictive disorder
* Diagnosed with psychiatric disorder
* Physical Status III-VI as defined by the ASA Physical Status Classification System
* Presence of acute infection or inflammatory condition (e.g., fever).
Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia

Eighty individuals (44 female, 36 male), which were randomly divided into 4 groups of 20 patients each, due to the treatment type: Botulinum toxin (BTX); Dry needling (DN); Pharmacological therapy (PT) and Manual therapy (MT). All treatments were carried out by the same maxillofacial surgeon. An informed consent form was obtained from all participants.

The study aimed to assess and compare the effectiveness of 4 different methods in the management bruxism: Botulinum toxin (BTX-A), dry needling (DN), pharmacological therapy (PT), and manual therapy (MT). 80 bruxist patients (44 female, 36 male) were randomly divided into 4 groups of 20 patients each. Botulinum toxin, dry needling, pharmacological therapy and manual therapy were carried out by the same maxillofacial surgeon in all patients. The following measurements were recorded by another investigator in each group, at baseline (before treatment) and at post-treatment intervals of 2nd, 4th, and 12th weeks; Visual Analogue Scale (VAS) for pain, maximum painless mouth opening (mm), Oral Health Impact Profile14 (OHIP-14).

Eligibility Criteria:
Inclusion Criteria:

* Adult patients aged 18 to 65 years with complete dentition,
* Patients classified as American Society of Anesthesiologists (ASA) physical status ASA I or ASA II
* Patients experiencing moderate to severe pain in the masticatory muscles related to bruxism,
* Patients who had not previously been treated for bruxism
* Patients who were diagnosed with bruxism were excluded from the study.

Exclusion Criteria:

* Presence of temporomandibular joint disorder
* Known allergy to botulinum toxin
* Pregnancy
* Presence of neuromuscular disease
* Chronic use of muscle relaxant medication within the last 3 months.
THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES

The Registry pretends to identify stratification, diagnosis and treatment approaches in patients with Acute Coronary Syndrome (ACS) in community hospitals with tertiary hospitals to optimize resources and identify strategies to improve health care quality through the creation of clinical guidelines that serve for unify management and treatment methods with adherence to international guidelines which include suggestions for treatment and medication.


Eligibility Criteria:
Inclusion Criteria:

all patients with suspected ACS and will analyze risk factors, chest pain and electrocardiographic characteristics.

Exclusion Criteria:

Patients with secondary ischemia (anaemia, pulmonary thromboembolism, myocarditis) and type II infarction.